Drug Combination Details
| General Information of the Combination (ID: C28729) | |||||
|---|---|---|---|---|---|
| Name | Miltefosine NP Info | + | Lopinavi Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Leishmaniasis
[ICD-11: 1F54]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | BALB/c mice were used in this study. | |||||
| Experimental
Result(s) |
LPV- MFS combination therapy can be effective in the treatment of VL/HIV co-infected patients and provides data that can help to guide a possible therapeutic strategy in VL/HIV co-infection. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: In vitro and in vivo Approaches. Front Cell Infect Microbiol. 2019 Jun 28;9:229. | |||
